Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SNPX - Synaptogenix provides update on phase 2b Alzheimer's disease trial

SNPX - Synaptogenix provides update on phase 2b Alzheimer's disease trial

Synaptogenix Inc.
Synaptogenix ([[SNPX]] +9.0%) announces an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD").The company has now dosed 58 of its target 100 patients, and seventeen sites continue to be live, Synaptogenix said.Additionally, the independent Data Safety Monitoring Board ("DSMB") overseeing the trial confirmed that 40 advanced AD patients have been dosed with Bryostatin without any significant safety issues.Shares of the company are trading up nearly 17% YTD.

For further details see:

Synaptogenix provides update on phase 2b Alzheimer's disease trial
Stock Information
Company Name: Synaptogenix Inc.
Stock Symbol: SNPX
Market: OTC
Website: synaptogen.com
Menu
SNPX SNPX Quote SNPX Short SNPX News SNPX Articles SNPX Message Board
Get SNPX Alerts

News, Short Squeeze, Breakout and More Instantly...